Close Menu

NEW YORK (GenomeWeb) – Curetis said today that its full-year 2018 revenues grew 17 percent year over year.

For the 12 months ended Dec. 31, 2018, the molecular diagnostics development firm reported revenues of €1.4 million ($1.6 million), up from €1.2 million in 2017.

The company said its R&D costs grew 43 percent year over year to €10.6 million from €7.4 million while its administrative costs were up 8 percent to €4.1 million from €3.8 million, and its distribution costs rose 12 percent to €8.2 million from €7.3 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The New York Times Magazine examines gender discrimination at the Salk Institute.

Science reports that MD Anderson Cancer Center has dismissed three researchers over foreign tie concerns.

A second death in gene therapy trial for type 1 spinal muscular atrophy is under investigation, according to Reuters.

In PLOS this week: antibiotic resistance patterns in Escherichia coli, a dozen genetic loci tied to varicose vein risk, and more.